1. Home
  2. PBMWW vs IMNM Comparison

PBMWW vs IMNM Comparison

Compare PBMWW & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBMWW
  • IMNM
  • Stock Information
  • Founded
  • PBMWW N/A
  • IMNM 2006
  • Country
  • PBMWW Canada
  • IMNM United States
  • Employees
  • PBMWW 10
  • IMNM N/A
  • Industry
  • PBMWW
  • IMNM Medicinal Chemicals and Botanical Products
  • Sector
  • PBMWW
  • IMNM Health Care
  • Exchange
  • PBMWW Nasdaq
  • IMNM Nasdaq
  • Market Cap
  • PBMWW N/A
  • IMNM 747.7M
  • IPO Year
  • PBMWW N/A
  • IMNM 2020
  • Fundamental
  • Price
  • PBMWW $0.01
  • IMNM $12.15
  • Analyst Decision
  • PBMWW
  • IMNM Strong Buy
  • Analyst Count
  • PBMWW 0
  • IMNM 4
  • Target Price
  • PBMWW N/A
  • IMNM $28.75
  • AVG Volume (30 Days)
  • PBMWW N/A
  • IMNM 856.4K
  • Earning Date
  • PBMWW N/A
  • IMNM 11-07-2024
  • Dividend Yield
  • PBMWW N/A
  • IMNM N/A
  • EPS Growth
  • PBMWW N/A
  • IMNM N/A
  • EPS
  • PBMWW N/A
  • IMNM N/A
  • Revenue
  • PBMWW N/A
  • IMNM $10,784,000.00
  • Revenue This Year
  • PBMWW N/A
  • IMNM N/A
  • Revenue Next Year
  • PBMWW N/A
  • IMNM N/A
  • P/E Ratio
  • PBMWW N/A
  • IMNM N/A
  • Revenue Growth
  • PBMWW N/A
  • IMNM 62.73
  • 52 Week Low
  • PBMWW N/A
  • IMNM $6.93
  • 52 Week High
  • PBMWW N/A
  • IMNM $30.96
  • Technical
  • Relative Strength Index (RSI)
  • PBMWW N/A
  • IMNM 36.28
  • Support Level
  • PBMWW N/A
  • IMNM $11.73
  • Resistance Level
  • PBMWW N/A
  • IMNM $12.46
  • Average True Range (ATR)
  • PBMWW 0.00
  • IMNM 0.74
  • MACD
  • PBMWW 0.00
  • IMNM -0.21
  • Stochastic Oscillator
  • PBMWW 0.00
  • IMNM 12.10

About PBMWW Psyence Biomedical Ltd. Warrant

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

About IMNM Immunome Inc.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.

Share on Social Networks: